Literature DB >> 1720853

Dexfenfluramine neurotoxicity in brains of non-human primates.

G A Ricaurte1, M E Molliver, M B Martello, J L Katz, M A Wilson, A L Martello.   

Abstract

Dexfenfluramine, a drug prescribed for appetite suppression, was evaluated in non-human primates for its potential to produce toxic effects on brain serotonin (5-HT) neurons. Squirrel monkeys received dexfenfluramine subcutaneously twice daily for four days at doses of 1.25 or 5.00 mg/kg. Two weeks later, a dose-related depletion of 5-HT and 5-hydroxyindoleacetic acid was found, together with a reduced number of 5-HT uptake sites. Morphological studies showed acute pathological changes in 5-HT axons, followed by a persistent decrease in 5-HT axon density. Our findings indicate that dexfenfluramine damages central 5-HT neurons in monkeys and raise concern about the potential neurotoxicity of this drug in man.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1720853     DOI: 10.1016/0140-6736(91)92301-h

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

1.  Acute and chronic D-fenfluramine treatments have different effects on serotonin synthesis rates in the rat brain: an autoradiographic study.

Authors:  F Yamane; Y Tohyama; M Diksic
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

2.  Alterations in the levels of monoamines in discrete brain regions of clomipramine-induced animal model of endogenous depression.

Authors:  M Vijayakumar; B L Meti
Journal:  Neurochem Res       Date:  1999-03       Impact factor: 3.996

3.  In vitro and in vivo characterisation of nor-beta-CIT: a potential radioligand for visualisation of the serotonin transporter in the brain.

Authors:  K A Bergström; C Halldin; H Hall; C Lundkvist; N Ginovart; C G Swahn; L Farde
Journal:  Eur J Nucl Med       Date:  1997-06

Review 4.  Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners.

Authors:  G Huether; D Zhou; E Rüther
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 5.  Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity.

Authors:  D McTavish; R C Heel
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

6.  Anorectic effect and brain concentrations of D-fenfluramine in the marmoset: relationship to the in vivo and in vitro effects on serotonergic mechanisms.

Authors:  S Caccia; M Anelli; C Fracasso; E Frittoli; P Giorcelli; M Gobbi; C Taddei; S Garattini; T Mennini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-03       Impact factor: 3.000

7.  Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats.

Authors:  M H Baumann; M A Ayestas; R B Rothman
Journal:  J Neurosci       Date:  1998-11-01       Impact factor: 6.167

8.  Effect of d-fenfluramine on the indole contents of the rat brain after treatment with different inducers of cytochrome P450 isoenzymes.

Authors:  M Anelli; C Fracasso; A Bergami; A Ferrarese; S Garattini; S Caccia
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

9.  p-Chloroamphetamine (PCA), 3,4-methylenedioxy-methamphetamine (MDMA) and d-fenfluramine pretreatment attenuates d-fenfluramine-evoked release of 5-HT in vivo.

Authors:  H G Series; P J Cowen; T Sharp
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

10.  Tolerance induction ameliorates allograft vasculopathy in rat aortic transplants. Influence of Fas-mediated apoptosis.

Authors:  L M Akyürek; C Johnsson; D Lange; P Georgii-Hemming; E Larsson; B C Fellström; K Funa; G Tufveson
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.